TNF and inflammatory bowel disease: Targeting these cytokines has been a major therapeutic strategy for managing IBD, leading to the development of biologic therapies that specifically inhibit IL-6 or TNF-α signaling pathways (Alhendi and Naser 2023; Shahini and Shahini 2023).